Biohaven Ltd.
About Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$738.8M
- Total assets
- $451.4M
- Market cap
- $1.6B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating income
- -$745.4M
- Income tax
- $1.4M
- Net income
- -$738.8M
- EPS (basic)
- $-6.86
- EPS (diluted)
- $-6.86
Balance sheet
- Total assets
- $451.4M
- Current assets
- $368.3M
- Total liabilities
- $399.4M
- Current liabilities
- $115.9M
- Shareholders’ equity
- $52.1M
Cash flow
- Operating cash flow
- -$609.4M
- Investing cash flow
- $300.6M
- Financing cash flow
- $439.1M
- Net cash flow
- $130.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.6B
- EPS (diluted)
- $-6.86
- Shares outstanding
- 146.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 23, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $738.8M.
- Trading 51% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Biohaven Ltd..
Write a review
News about Biohaven Ltd.
News & sentiment via Polygon.io
